Wise Practice of Chinese Hemodialysis (WISHES)

Overview

The investigators are registering all HD patients at recruited hospitals and developing a HD database in China. Patients will be follow-up every 3 months, and both baseline and follow-up information will be entered into the registration system. The patient survival, technical survival, patency rate of access, quality of life and residual renal function for HD patients will be compared using the HD database.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2026

Detailed Description

The investigators are registering all end stage renal disease (ESRD) patients receiving hemodialysis (HD) treatment, and developing a HD database in China. Patients' demographic characteristics (including age, gender, height, weight, BMI, smoking, drinking, and education), clinical characteristics (including systolic blood pressure, diastolic blood pressure, primary cause of ESRD, and lab measurements of serum, urine, and access patency), complications, drug information and scores of quality of life at the baseline will be collected. Patients will be follow-up every 3 month, the demographic and clinical characteristics, complications and drug information of patients will be collected at each visit. The investigators also record the outcome at each visit, such as mortality (including all-cause mortality and cardiovascular disease mortality), technical survival, kidney transplantation, transfer to peritoneal dialysis, hospitalization, access failure´╝îetc. The patient survival, technical survival, patency rate of access, quality of life and residual renal function for HD patients will be compared using the HD database.

Interventions

  • Other: No intervention
    • Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.

Arms, Groups and Cohorts

  • Hemodialysis patients
    • End stage renal disease patients receiving hemodialysis treatment

Clinical Trial Outcome Measures

Primary Measures

  • Patient survival of HD patients
    • Time Frame: 10 years

Secondary Measures

  • Quality of life evaluated using SF36 scale for HD patients
    • Time Frame: 10 years
  • Patency rate of access for HD patients
    • Time Frame: 10 years

Participating in This Clinical Trial

Inclusion Criteria

End stage renal disease patients receiving hemodialysis treatment. Exclusion Criteria:

No

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sun Yat-sen University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Xue Qing Yu, Professor – Sun Yat-sen University
  • Overall Contact(s)
    • Xueqing Yu, M.D. & Ph.D., yuxq@mail.sysu.edu.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.